Search research articles
Contact Us
Filters
Showing results (61-70 of 150) with videos related to
Page
of 15
Sort By:
European Journal of Haematology
|
March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
Meletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
Amanda Psyrri, Aris Bamias, Ziwei Yu, et al.
European Urology Oncology
|
August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
Eleni Efstathiou, Mark Titus, Sijin Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
Eleni Efstathiou, Mark Titus, Dimitra Tsavachidou, et al.
European Urology
|
July 15, 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301
Bruce Montgomery, Thian Kheoh, Arturo Molina, et al.
The Prostate
|
December 20, 2024
The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM Staging
Sajeev Sridhar, Zeyad Abouelfetouh, Ion Codreanu, et al.
European Urology
|
October 27, 2009
Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification
Eleni Efstathiou, Neil A Abrahams, Rita F Tibbs, et al.
The Journal of Urology
|
February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Future Oncology (London, England)
|
August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Future Oncology (London, England)
|
June 15, 2022
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial
Raj Satkunasivam, Kelvin Lim, Bin S Teh, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 150) with videos related to
Sort By:
Page
of 15
European Journal of Haematology
|
March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
Meletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
Amanda Psyrri, Aris Bamias, Ziwei Yu, et al.
European Urology Oncology
|
August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
Eleni Efstathiou, Mark Titus, Sijin Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
Eleni Efstathiou, Mark Titus, Dimitra Tsavachidou, et al.
European Urology
|
July 15, 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301
Bruce Montgomery, Thian Kheoh, Arturo Molina, et al.
The Prostate
|
December 20, 2024
The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM Staging
Sajeev Sridhar, Zeyad Abouelfetouh, Ion Codreanu, et al.
European Urology
|
October 27, 2009
Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification
Eleni Efstathiou, Neil A Abrahams, Rita F Tibbs, et al.
The Journal of Urology
|
February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Future Oncology (London, England)
|
August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Future Oncology (London, England)
|
June 15, 2022
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial
Raj Satkunasivam, Kelvin Lim, Bin S Teh, et al.
Page
of 15